🧫
Ketamine in pediatric TRD patients
active
experiment
Created: 2026-04-10T22:47:07
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-143455d7-0085-4933-ae46-60dfd99f457c
🧫 Experiment Protocol
Clinicaltreatment-resistant depressionpediatric patientsproposed
Clinical assessment of ketamine and esketamine safety and efficacy in pediatric patients with treatment-resistant depression. This specialized population study examined the use of NMDA receptor antagonists in children and adolescents who had not responded to standard antidepressant treatments. The research focused on age-appropriate dosing, developmental considerations, and the unique risk-benefit profile in younger patients, including assessment of potential impacts on developing neural systems and long-term safety concerns specific to pediatric populations.
PRIMARY OUTCOME
antidepressant efficacy and safety
EXPECTED OUTCOMES
Effective antidepressant response with acceptable pediatric safety profile
SUCCESS CRITERIA
Demonstration of efficacy with minimal adverse effects appropriate for pediatric use
PROTOCOL
Pediatric-adapted ketamine/esketamine administration with specialized monitoring protocols
Source: PMID 41935374 ↗
🧫 Experiment Extras
PATHWAY
NMDA receptor signaling
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.